OTC Markets OTCPK - Delayed Quote USD

Almirall, S.A. (LBTSF)

Compare
9.51 0.00 (0.00%)
At close: October 15 at 4:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for LBTSF

Recent News: LBTSF

View More
Almirall completes EU regulatory procedure for antifungal Jublia

Almirall completes EU regulatory procedure for antifungal Jublia
Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe

Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe
New Data Show Almirall′s EBGLYSS? (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis

New Data Show Almirall′s EBGLYSS? (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis
Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress

Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress
Almirall And Two Additional Stocks Considered Below Estimated Market Value

Almirall And Two Additional Stocks Considered Below Estimated Market Value
Ilumetri and Ebglyss spur Almirall’s growth in dermatology

Ilumetri and Ebglyss spur Almirall’s growth in dermatology
Almirall’s H1 2024 Results: Almirall Delivers Strong Performance in the First Half of 2024, Achieving Net Sales Growth of 6.7% Driven by Its European Dermatology Business and Accelerating Biologics Sales

Almirall’s H1 2024 Results: Almirall Delivers Strong Performance in the First Half of 2024, Achieving Net Sales Growth of 6.7% Driven by Its European Dermatology Business and Accelerating Biologics Sales
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
NICE recommends Ebglyss for atopic dermatitis patients

NICE recommends Ebglyss for atopic dermatitis patients
NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe Atopic Dermatitis in the NHS England in Eligible Adolescents and Adults

NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe Atopic Dermatitis in the NHS England in Eligible Adolescents and Adults
Almirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030

Almirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030
View More

Related Tickers